Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez-Martín JL, León A, García A, Vázquez L, Sierra J, San Miguel JF, Grupo Español de Mieloma. Leukemia 20(3):542-5. FI: 8.296 (Q1) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol Alvarez I, Sureda A, Caballero D, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubio-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Biology of Blood and Marrow 12(2):172-83. FI: 3.149 (Q2) Chronic graft-versus-host disease: Pathogenesis and clinical management Pérez-Simón JA, Sánchez-Abarca I, Díez-Campelo M, Caballero D, San Miguel J. Drugs 66(8):1041-57. FI: 4.732 (Q1) Prognostic impact of pretransplantation computed tomography and gallium scans in patients with Hodgkin lymphoma with poor prognosis undergoing hematopoietic stem cell transplantation Escobar IG, Caballero D, Tamayo P, Pérez-Simón JA, Mateos MV, García JR, San Miguel JF. Clinical Lymphoma & Myeloma 7(3):217-25. FI: 1.130 (Q4) Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, Holliger P, Álvarez-Vallina L. Cancer Gene Therapy 14(4):380-8. FI: 3.126 (Q2) A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, Facon T, Fanin R, Caballero D, Ben-Yehuda D, Giles F. Leukemia & Lymphoma 48(1):39-45. FI: 2.397 (Q3) Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A,Caballero D, Sierra J, Ribera JM, Diez JL. Biology of Blood and Marrow 13(6):701-6. FI: 3.149 (Q2) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero D. Annals of Oncology 18(4):652-7. FI: 5.647 (Q1) Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, León A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Canigral G, Bergua J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Medula Osea. European Journal of Haematology 78(4):290-6. FI: 2.345 (Q3) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea(GEL-TAMO). European Journal of Haematology 79(1):32-8. FI: 2.345 (Q3)
|
